-+ 0.00%
-+ 0.00%
-+ 0.00%

Silo Pharma highlights SPC-15 PTSD program after Trump order on psychedelic research

PUBT·04/20/2026 10:45:58
Listen to the news
Silo Pharma highlights SPC-15 PTSD program after Trump order on psychedelic research
  • Silo Pharma highlighted its PTSD drug program SPC-15 following President Trump executive order signed April 18, 2026 directing US agencies to accelerate psychedelic-therapy research and patient access.
  • SPC-15 targets prophylactic treatment of PTSD using intranasal delivery designed for rapid nose-to-brain CNS exposure.
  • Development plan uses 505(b)(2) regulatory pathway, with IND engagement with FDA in preparation.
  • CEO Eric Weisblum said federal momentum on psychedelic therapeutics could improve regulatory and clinical conditions for Silo pipeline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief on April 20, 2026, and is solely responsible for the information contained therein.